These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21220328)

  • 1. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
    Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
    Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
    PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
    Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
    BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
    McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
    Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.
    Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP
    Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
    Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
    Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
    Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
    J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMI1 sustains human glioblastoma multiforme stem cell renewal.
    Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
    J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of genome-wide genechip for screening and identifying genes related to CD133(+)CD200(+) colorectal cancer stem cells].
    Zhang S; Li L; Huang Z; Xin X; Xiao B
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1787-91. PubMed ID: 24369246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
    Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
    Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
    Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
    Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.